Kamada developed a plasma-derived, investigational antibody treatment for COVID-19 currently under trial; interim results show promise.

The trial involves 12 hospitalized but non-ventilated COVID-19 patients with pneumonia; 11 of them have been discharged, Kamada says.

Hadassah hospital gave 3 people a new drug made from antibodies from people who had had coronavirus; they are all now home after an ‘astonishing’ recovery.

The Rehovot-based firm said it completed the manufacturing of the first batch of its plasma-derived IgG product for the novel coronavirus.

BATM said it began filling initial shipping initial orders and will be 'ramping up production for larger quantities' for European customers.